Robert Scott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert Scott has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Guruprasad Padur Aithal
Department of Hepatology Nottingham University Hospitals NHS Trust Nottingham UK
5 shared publications - Indra Neil Guha
NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom
3 shared publications A Austin
1 shared publicationA Lawson
Derby Digestive Diseases Centre, Royal Derby Hospital
1 shared publicationAdam Figgins
H 8 Department of Pathology , Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus , Nottingham , UK
1 shared publication- Adolfo Parra-Blanco
NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust, nottingham, United Kingdom of Great Britain and Northern Ireland
1 shared publication
Latest Publications
P97 Transient elastography in community alcohol services: can it be an adjunct and impact drinking behaviour?
Introduction Alcohol is the leading cause of cirrhosis in western populations. Early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elastography (TE) into community alcohol services and to determine its impact on modifying drinking behaviours. Method A prospective cohort study was conducted at a community alcohol clinic in Nottingham (April-2012 to March-2014). Patients (>18years) with a primary alcohol problem were recruited. Those known to liver services or to have chronic liver disease were excluded. Significant liver fibrosis was defined by a liver stiffness measure (LSM) of >8 kilopascals (kPa). Follow-up was for a minimum of six months. Data were descriptively analysed for significant differences between patients with a normal LSM versus raised LSM. Results 156 patients were invited; n=87 attended and n=86 underwent successful TE. The majority were male (n=53, 70.0%) and the mean age was 46.3 years (SD +/-9.8). Median liver stiffness was 6.9kPa. Clinically significant liver fibrosis was identified in n=33 (38.4%), of which n=6 were in cirrhotic range (≥15 kPa). Baseline median self-reported alcohol intake for normal stiffness was 126 units per week and in raised stiffness was 149.0 units per week the difference was non-significant (p=0.338). Median reduction in self-report alcohol intake in whole cohort was 65.0 units per week (p=Conclusion The study demonstrated that transient elastography is a feasible tool to stratify clinically significant liver disease in community alcohol services. It can stimulate a change in high-risk drinking behaviour and a normal liver stiffness result does not provide false reassurance to participants. Comparison of cohorts
P97 Transient elastography in community alcohol services: can it be an adjunct and impact drinking behaviour?
Introduction Alcohol is the leading cause of cirrhosis in western populations. Early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elastography (TE) into community alcohol services and to determine its impact on modifying drinking behaviours. Method A prospective cohort study was conducted at a community alcohol clinic in Nottingham (April-2012 to March-2014). Patients (>18years) with a primary alcohol problem were recruited. Those known to liver services or to have chronic liver disease were excluded. Significant liver fibrosis was defined by a liver stiffness measure (LSM) of >8 kilopascals (kPa). Follow-up was for a minimum of six months. Data were descriptively analysed for significant differences between patients with a normal LSM versus raised LSM. Results 156 patients were invited; n=87 attended and n=86 underwent successful TE. The majority were male (n=53, 70.0%) and the mean age was 46.3 years (SD +/-9.8). Median liver stiffness was 6.9kPa. Clinically significant liver fibrosis was identified in n=33 (38.4%), of which n=6 were in cirrhotic range (≥15 kPa). Baseline median self-reported alcohol intake for normal stiffness was 126 units per week and in raised stiffness was 149.0 units per week the difference was non-significant (p=0.338). Median reduction in self-report alcohol intake in whole cohort was 65.0 units per week (p=Conclusion The study demonstrated that transient elastography is a feasible tool to stratify clinically significant liver disease in community alcohol services. It can stimulate a change in high-risk drinking behaviour and a normal liver stiffness result does not provide false reassurance to participants. Comparison of cohorts
- 16 December 2020
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 53 (5) , 1422-1431
MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability
Background: Increased small bowel permeability leads to bacterial translocation, associated with significant morbidity and mortality. Biomarkers are needed to evaluate these changes in vivo, stratify an individual's risk, and evaluate the efficacy of interventions. MRI is an established biomarker of small bowel inflammation.Purpose: To characterize changes in the small bowel with quantitative MRI measures associated with increased permeability induced by indomethacin.Study Type: Prospective single‐center, double‐blind, two‐way crossover provocation study.Subjects: A provocation cohort (22 healthy volunteers) and intrasubject reproducibility cohort (8 healthy volunteers).Field Strength/Sequence: 2D balanced turbo field echo sequences to measure small bowel wall thickness, T2, and motility acquired at 3T.Assessment: Participants were randomized to receive indomethacin or placebo prior to assessment. After a minimum 2‐week washout, measures were repeated with the alternative allocation. MR measures (wall thickness, T2, motility) at each study visit were compared to the reference standard 2‐hour lactulose/mannitol urinary excretion ratio (LMR) test performed by a lab technician. All analyses were performed blind.Statistical Tests: Normality was tested (Shapiro–Wilk's test). Paired testing (Student's t‐test or Wilcoxon) determined the significance of paired differences with indomethacin provocation. Pearson's correlation coefficient compared significant measures with indomethacin provocation to LMR. Intrasubject (intraclass correlation) and interrater variability (Bland–Altman) were assessed.Results: Indomethacin provocation induced a significant increase in LMR compared to placebo (P < 0.05) and a significant increase in small bowel T2 (0.12 seconds compared to placebo 0.07 seconds, P < 0.05). Small bowel wall thickness (P = 0.17) and motility (P = 0.149) showed no significant change. T2 and LMR were positively correlated (r = 0.68, P < 0.05). T2 measurements were robust to interobserver (intraclass correlation 0.89) and intrasubject variability (Bland–Altman bias of 0.005 seconds, 95% confidence interval [CI] –0.04 to +0.05 seconds, and 0.0006 seconds, 95% CI –0.05 to +0.06 seconds).Data Conclusion: MR measures of small bowel wall T2 were significantly increased following indomethacin provocation and correlated with 2‐hour LMR test results.Level of Evidence: 1Technical Efficacy Stage: 2
- 16 December 2020
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 53 (5) , 1422-1431
MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability
Background: Increased small bowel permeability leads to bacterial translocation, associated with significant morbidity and mortality. Biomarkers are needed to evaluate these changes in vivo, stratify an individual's risk, and evaluate the efficacy of interventions. MRI is an established biomarker of small bowel inflammation.Purpose: To characterize changes in the small bowel with quantitative MRI measures associated with increased permeability induced by indomethacin.Study Type: Prospective single‐center, double‐blind, two‐way crossover provocation study.Subjects: A provocation cohort (22 healthy volunteers) and intrasubject reproducibility cohort (8 healthy volunteers).Field Strength/Sequence: 2D balanced turbo field echo sequences to measure small bowel wall thickness, T2, and motility acquired at 3T.Assessment: Participants were randomized to receive indomethacin or placebo prior to assessment. After a minimum 2‐week washout, measures were repeated with the alternative allocation. MR measures (wall thickness, T2, motility) at each study visit were compared to the reference standard 2‐hour lactulose/mannitol urinary excretion ratio (LMR) test performed by a lab technician. All analyses were performed blind.Statistical Tests: Normality was tested (Shapiro–Wilk's test). Paired testing (Student's t‐test or Wilcoxon) determined the significance of paired differences with indomethacin provocation. Pearson's correlation coefficient compared significant measures with indomethacin provocation to LMR. Intrasubject (intraclass correlation) and interrater variability (Bland–Altman) were assessed.Results: Indomethacin provocation induced a significant increase in LMR compared to placebo (P < 0.05) and a significant increase in small bowel T2 (0.12 seconds compared to placebo 0.07 seconds, P < 0.05). Small bowel wall thickness (P = 0.17) and motility (P = 0.149) showed no significant change. T2 and LMR were positively correlated (r = 0.68, P < 0.05). T2 measurements were robust to interobserver (intraclass correlation 0.89) and intrasubject variability (Bland–Altman bias of 0.005 seconds, 95% confidence interval [CI] –0.04 to +0.05 seconds, and 0.0006 seconds, 95% CI –0.05 to +0.06 seconds).Data Conclusion: MR measures of small bowel wall T2 were significantly increased following indomethacin provocation and correlated with 2‐hour LMR test results.Level of Evidence: 1Technical Efficacy Stage: 2
- Open Access
- 2 December 2018
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (12) , 1611-1618
Narrow band imaging and serology in the assessment of premalignant gastric pathology
Background: Patient outcomes in gastric adenocarcinoma are poor due to late diagnosis. Detecting and treating at the premalignant stage has the potential to improve this. Helicobacter pylori is also a strong risk factor for this disease. Aims: Primary aims were to assess the diagnostic accuracy of magnified narrow band imaging (NBI-Z) endoscopy and serology in detecting normal mucosa, H. pylori gastritis and gastric atrophy. Secondary aims were to compare the diagnostic accuracies of two classification systems using both NBI-Z and white light endoscopy with magnification (WLE-Z) and evaluate the inter-observer agreement. Methods: Patients were prospectively recruited. Images of gastric mucosa were stored with histology and serum for IgG H. pylori and Pepsinogen (PG) I/II ELISAs. Blinded expert endoscopists agreed on mucosal pattern. Mucosal images and serological markers were compared with histology. Kappa statistics determined inter-observer variability for randomly allocated images among four experts and four non-experts. Results: 116 patients were prospectively recruited. Diagnostic accuracy of NBI-Z for determining normal gastric mucosa was 0.87(95%CI 0.82–0.92), H. pylori gastritis 0.65(95%CI 0.55–0.75) and gastric atrophy 0.88(95%CI 0.81–0.94). NBI-Z was superior to serology at detecting gastric atrophy: NBI-Z gastric atrophy 0.88(95%CI 0.81-0.94) vs PGI/II ratio < 3 0.74(95%CI 0.62–0.85) p<.0001. Overall NBI-Z was superior to WLE-Z in detecting disease using two validated classifications. Inter-observer agreement was 0.63(95%CI 0.51–0.73). Conclusions: NBI-Z accurately detects changes in the GI mucosa which currently depend on histology. NBI-Z is useful in the detection of precancerous conditions, potentially improving patient outcomes with early intervention to prevent gastric cancer.
- 2 December 2018
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (12) , 1611-1618
Open AccessNarrow band imaging and serology in the assessment of premalignant gastric pathology
Background: Patient outcomes in gastric adenocarcinoma are poor due to late diagnosis. Detecting and treating at the premalignant stage has the potential to improve this. Helicobacter pylori is also a strong risk factor for this disease. Aims: Primary aims were to assess the diagnostic accuracy of magnified narrow band imaging (NBI-Z) endoscopy and serology in detecting normal mucosa, H. pylori gastritis and gastric atrophy. Secondary aims were to compare the diagnostic accuracies of two classification systems using both NBI-Z and white light endoscopy with magnification (WLE-Z) and evaluate the inter-observer agreement. Methods: Patients were prospectively recruited. Images of gastric mucosa were stored with histology and serum for IgG H. pylori and Pepsinogen (PG) I/II ELISAs. Blinded expert endoscopists agreed on mucosal pattern. Mucosal images and serological markers were compared with histology. Kappa statistics determined inter-observer variability for randomly allocated images among four experts and four non-experts. Results: 116 patients were prospectively recruited. Diagnostic accuracy of NBI-Z for determining normal gastric mucosa was 0.87(95%CI 0.82–0.92), H. pylori gastritis 0.65(95%CI 0.55–0.75) and gastric atrophy 0.88(95%CI 0.81–0.94). NBI-Z was superior to serology at detecting gastric atrophy: NBI-Z gastric atrophy 0.88(95%CI 0.81-0.94) vs PGI/II ratio < 3 0.74(95%CI 0.62–0.85) p<.0001. Overall NBI-Z was superior to WLE-Z in detecting disease using two validated classifications. Inter-observer agreement was 0.63(95%CI 0.51–0.73). Conclusions: NBI-Z accurately detects changes in the GI mucosa which currently depend on histology. NBI-Z is useful in the detection of precancerous conditions, potentially improving patient outcomes with early intervention to prevent gastric cancer.
- Open Access
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , 1848-1850
Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , 1848-1850
Open AccessPretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S545-S546
Direct acting anti-viral treatment for hepatitis C results in a rapid reduction in MRI measures of hepatic microstructure
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S545-S546
Direct acting anti-viral treatment for hepatitis C results in a rapid reduction in MRI measures of hepatic microstructure
- 3 May 2017
- Published by S. Karger AG in Digestive Diseases
- Vol. 35 (4) , 314-322
Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine
Background: In the past decades, a number of non-invasive methods have emerged for detecting and estimating liver fibrosis; these include both serum-based panels and imaging-based technology. Some of these methods are now being incorporated in clinical practice. However, the limitations of the current techniques include lack of organ specificity, sampling errors and limited ability to reflect the efficacy of interventions. Key Messages: Novel magnetic resonance (MR)-based techniques provide an opportunity to bring about further changes in the investigations and management of patients with liver diseases. Multimodal quantitative MR techniques enable the estimation of fat, iron accumulation, degree of liver injury/inflammation and fibrosis within the whole liver without the need for administering contrast agents. Architectural changes within the liver can be evaluated concurrently with portal haemodynamic changes allowing non-invasive assessment of portal hypertension and effects of interventions. A combination ultra-high field (7T) provides greater sensitivity with a potential to distinguish inflammation from fibrosis on imaging and determine specific types of fats (saturated vs. unsaturated) present within the liver using MR spectroscopy. 13C MR spectroscopy can estimate glutathione flux and rate of beta oxidation in-vivo providing novel tools for experimental studies that evaluate the efficacy of interventions as well as underlying mechanisms. Conclusions: Translational research should focus on converting the potentials of these innovative methodologies into clinical applications for the benefit of patients.
- 3 May 2017
- Published by S. Karger AG in Digestive Diseases
- Vol. 35 (4) , 314-322
Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine
Background: In the past decades, a number of non-invasive methods have emerged for detecting and estimating liver fibrosis; these include both serum-based panels and imaging-based technology. Some of these methods are now being incorporated in clinical practice. However, the limitations of the current techniques include lack of organ specificity, sampling errors and limited ability to reflect the efficacy of interventions. Key Messages: Novel magnetic resonance (MR)-based techniques provide an opportunity to bring about further changes in the investigations and management of patients with liver diseases. Multimodal quantitative MR techniques enable the estimation of fat, iron accumulation, degree of liver injury/inflammation and fibrosis within the whole liver without the need for administering contrast agents. Architectural changes within the liver can be evaluated concurrently with portal haemodynamic changes allowing non-invasive assessment of portal hypertension and effects of interventions. A combination ultra-high field (7T) provides greater sensitivity with a potential to distinguish inflammation from fibrosis on imaging and determine specific types of fats (saturated vs. unsaturated) present within the liver using MR spectroscopy. 13C MR spectroscopy can estimate glutathione flux and rate of beta oxidation in-vivo providing novel tools for experimental studies that evaluate the efficacy of interventions as well as underlying mechanisms. Conclusions: Translational research should focus on converting the potentials of these innovative methodologies into clinical applications for the benefit of patients.
- Open Access
- 1 December 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 65 (6) , 1131-1139
Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging
- 1 December 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 65 (6) , 1131-1139
Open AccessNon-invasive assessment of portal hypertension using quantitative magnetic resonance imaging
- 1 January 2015
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 45 (1) , 49-54
Enteral tube feeding in adults
Enteral tube feeding is usually a relatively straightforward method of nutritional support, and should be facilitated by a multiprofessional team. For short-term use (<4 weeks) a fine bore feeding nasogastric tube is indicated but if longer term feeding is required then a gastrostomy is appropriate, usually inserted endoscopically (a percutaneous endoscopic gastrostomy tube). The most common serious complication of a nasogastric tube is not identifying a misplaced tube within the lungs: there are clear recommendations from the National Patient Safety Agency as to how to check tube placement. Nasojejunal tubes are required in patients with gastroparesis. Tube blockage is common and is prevented by careful and regular flushing. Diarrhoea is the most complication of feeding and is often related to other medication. Clinicians need an algorithm for systematically dealing with such a problem. Refeeding syndrome may occur in malnourished patients and is characterised by low levels of potassium, phosphate, and/or magnesium, as well as disorders of water and salt balance. Identifying the at-risk patient with careful monitoring is crucial.
- 1 January 2015
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 45 (1) , 49-54
Enteral tube feeding in adults
Enteral tube feeding is usually a relatively straightforward method of nutritional support, and should be facilitated by a multiprofessional team. For short-term use (<4 weeks) a fine bore feeding nasogastric tube is indicated but if longer term feeding is required then a gastrostomy is appropriate, usually inserted endoscopically (a percutaneous endoscopic gastrostomy tube). The most common serious complication of a nasogastric tube is not identifying a misplaced tube within the lungs: there are clear recommendations from the National Patient Safety Agency as to how to check tube placement. Nasojejunal tubes are required in patients with gastroparesis. Tube blockage is common and is prevented by careful and regular flushing. Diarrhoea is the most complication of feeding and is often related to other medication. Clinicians need an algorithm for systematically dealing with such a problem. Refeeding syndrome may occur in malnourished patients and is characterised by low levels of potassium, phosphate, and/or magnesium, as well as disorders of water and salt balance. Identifying the at-risk patient with careful monitoring is crucial.
- 23 October 2014
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 112 (1) , 97-106
Non-invasive monitoring of liver fibrosis
Introduction Assessing the formation and regression of fibrosis in chronic liver disease (CLD) is important. Current methods of assessment employed in clinical practice are inadequate. We present a review of the utility of non-invasive biomarkers of liver fibrosis. Sources of data Published material on MEDLINE. Areas of agreement Liver biopsy is an imperfect ‘gold standard’. Biomarkers are excellent at detecting significant fibrosis across different aetiologies of CLD. There is growing evidence that they also predict clinical outcomes. Areas of controversy Non-invasive biomarkers can be used in clinical practice to screen for significant fibrosis, but the utility of liver biopsy is retained in answering specific questions. Biomarkers cannot be used robustly in clinical trials as doubts remain over their ability to detect small changes in fibrosis, inflammation and what influences them. Areas timely for developing research Community screening and algorithms are being developed with biomarkers to more effectively direct resources. Novel imaging techniques have huge potential advantages, particularly in secondary care for risk stratification.
- 23 October 2014
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 112 (1) , 97-106
Non-invasive monitoring of liver fibrosis
Introduction Assessing the formation and regression of fibrosis in chronic liver disease (CLD) is important. Current methods of assessment employed in clinical practice are inadequate. We present a review of the utility of non-invasive biomarkers of liver fibrosis. Sources of data Published material on MEDLINE. Areas of agreement Liver biopsy is an imperfect ‘gold standard’. Biomarkers are excellent at detecting significant fibrosis across different aetiologies of CLD. There is growing evidence that they also predict clinical outcomes. Areas of controversy Non-invasive biomarkers can be used in clinical practice to screen for significant fibrosis, but the utility of liver biopsy is retained in answering specific questions. Biomarkers cannot be used robustly in clinical trials as doubts remain over their ability to detect small changes in fibrosis, inflammation and what influences them. Areas timely for developing research Community screening and algorithms are being developed with biomarkers to more effectively direct resources. Novel imaging techniques have huge potential advantages, particularly in secondary care for risk stratification.
- Open Access
- 18 April 2013
- Published by BMJ in Frontline Gastroenterology
- Vol. 4 (3) , 191-197
Acute kidney injury is independently associated with death in patients with cirrhosis
Background and aims Current creatine-based criteria for defining acute kidney injury (AKI) are validated in general hospitalised patients but their application to cirrhotics (who are younger and have reduced muscle mass) is less certain. We aimed to evaluate current definitions of AKI (acute kidney injury network (AKIN) criteria) in a population of cirrhotic patients and correlate this with outcomes. Methods We prospectively identified patients with AKI and clinical, radiological or histological evidence of cirrhosis. We compared them with a control group with evidence of cirrhosis and no AKI. Results 162 cirrhotic patients were studied with a mean age of 56.8±14 years. They were predominantly male (65.4%) with alcoholic liver disease (78.4%). 110 patients had AKI: 44 stage 1, 32 stage 2 and 34 stage 3. They were well matched in age, sex and liver disease severity with 52 cirrhotics without AKI. AKI was associated with increased mortality (31.8% vs 3.8%, pConclusions The utility of AKIN criteria is maintained in cirrhotic patients. Decompensated liver disease and AKI appear to be independent variables predicting death in cirrhotics.
- 18 April 2013
- Published by BMJ in Frontline Gastroenterology
- Vol. 4 (3) , 191-197
Open AccessAcute kidney injury is independently associated with death in patients with cirrhosis
Background and aims Current creatine-based criteria for defining acute kidney injury (AKI) are validated in general hospitalised patients but their application to cirrhotics (who are younger and have reduced muscle mass) is less certain. We aimed to evaluate current definitions of AKI (acute kidney injury network (AKIN) criteria) in a population of cirrhotic patients and correlate this with outcomes. Methods We prospectively identified patients with AKI and clinical, radiological or histological evidence of cirrhosis. We compared them with a control group with evidence of cirrhosis and no AKI. Results 162 cirrhotic patients were studied with a mean age of 56.8±14 years. They were predominantly male (65.4%) with alcoholic liver disease (78.4%). 110 patients had AKI: 44 stage 1, 32 stage 2 and 34 stage 3. They were well matched in age, sex and liver disease severity with 52 cirrhotics without AKI. AKI was associated with increased mortality (31.8% vs 3.8%, pConclusions The utility of AKIN criteria is maintained in cirrhotic patients. Decompensated liver disease and AKI appear to be independent variables predicting death in cirrhotics.